title: Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer.
abstract: Anticancer drugs may frequently induce host immunosuppression and symptomatic toxicities. Once symptomatic toxicity occurs, the patient's quality-of-life (QOL) is reduced. Since little is known of the relationship between host immunity and the toxicity of chemotherapy, the host immunity before and after chemotherapy was compared to assess whether it is related to symptomatic toxicity during chemotherapy.
  
  
  METHODS
  Fourteen patients with colorectal cancer underwent leucovorin /5-fluorouracil (LV/5-FU) treatment, or S-1/irinotecan (CPT-11). Host immunity (cytokine production of peripheral blood mononuclear cell (PBMC), serum soluble interleukin-2 receptor (sIL-2R) levels and phenotypic analyses of PBMC were measured before and after the first chemotherapy.
  
  
  RESULTS
  An increase of sIL-2R, CD4+CD25+ T-cells and the CD4/8 ratio in patients with symptomatic adverse reactions were found. These changes in the first chemotherapy were significantly different (p = 0.0211, p = 0.0087, p = 0.0234).
  
  
  CONCLUSIONS
  The current study indicated that there are some parameters correlated with toxicity during chemotherapy which effect QOL. In such patients, negative influences on host immunity, such as an increase of sIL-2R and regulatory T-cells, and a decrease of cytotoxic T-cells could occur.
authors.affiliation: Department of Surgery, Tokyo Women's Medical University Medical Center East, 2-1-10 Nishiogu, Arakawaku, Tokyo 116-8567, Japan.
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yoshimatsu
authors.forename: Kotaro
authors.initials: K
authors.lastname: Kuhara
authors.forename: Hiroko
authors.initials: H
authors.lastname: Itagaki
authors.forename: Masaki
authors.initials: M
authors.lastname: Aizawa
authors.forename: Hajime
authors.initials: H
authors.lastname: Yokomizo
authors.forename: Takashi
authors.initials: T
authors.lastname: Fujimoto
authors.forename: Taisuke
authors.initials: T
authors.lastname: Otani
authors.forename: Gakuji
authors.initials: G
authors.lastname: Osawa
authors.forename: Rie
authors.initials: R
authors.lastname: Kobayashi
authors.forename: Kenji
authors.initials: K
authors.lastname: Ogawa
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D016516:CD4-CD8 Ratio; D002166:Camptothecin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D016207:Cytokines / Q000096:biosynthesis; D004338:Drug Combinations; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D011788:Quality of Life; D015375:Receptors, Interleukin-2 / Q000096:biosynthesis / Q000097:blood; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D016207:Cytokines; D004338:Drug Combinations; D015375:Receptors, Interleukin-2; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin